Trial Profile
A Pilot Trial of YF476, A Gastrin Antagonist, In Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Netazepide (Primary)
- Indications Carcinoma; Gastric cancer; Neuroendocrine tumours
- Focus Biomarker; Therapeutic Use
- Sponsors Trio Medicines
- 14 Aug 2019 Status changed from recruiting to discontinued.
- 14 Aug 2019 Status changed from recruiting to discontinued.
- 30 Mar 2011 New trial record